FDA Approves Baxter International, Inc.’s FLEXBUMIN 5%, First And Only 5% Human Albumin Solution In A Flexible Container

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International, Inc. (NYSE:BAX) today announced that the United States Food and Drug Administration (FDA) has approved FLEXBUMIN® [Albumin (Human)], USP, 5% Solution. FLEXBUMIN 5% is indicated for hypovolemia, hypoalbuminemia due to general causes, burns and in patients undergoing cardiopulmonary bypass surgery.

Help employers find you! Check out all the jobs and post your resume.